Investor's Business Daily on MSN
Why Ligand Pharma, A Hidden Name Behind Two Big Drugs, Is Up 92% This Year
Shares of Ligand PharmaceuticalsLGND are absolutely flying, up more than 92% this year, as investors line up behind the ...
Travere Therapeutics reported third-quarter 2025 earnings, highlighting revenue of US$164.86 million and net income of US$25.71 million, a sharp turnaround from the net loss a year earlier, with ...
Travere Therapeutics recently received accelerated approval for Filspari (sparsentan) for the treatment of IgA Nephropathy (IgAN) and raised $200 million in a public offering. The company may struggle ...
The U.S. Food and Drug Administration (FDA) granted accelerated approval to Travere Therapeutics' (NASDAQ:TVTX) oral medicine Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at ...
(RTTNews) - Travere Therapeutics Inc. (TVTX) said that the U.S. Food and Drug Administration granted accelerated approval to Filspari (sparsentan) to reduce proteinuria in adults with primary IgA ...
New late-breaking data from DUPLEX Study show significantly more FILSPARI ® (sparsentan)-treated patients achieved proteinuria below 0.7 g/g compared with irbesartan FILSPARI treatment associated with ...
TipRanks on MSN
Travere Therapeutics’ Strong Quarter and Future Prospects
Travere Therapeutics, Inc. (($TVTX)) has held its Q3 earnings call. Read on for the main highlights of the call. Travere Therapeutics, Inc.
Sparsentan is an endothelin and angiotensin II receptor antagonist. The Food and Drug Administration (FDA) has granted accelerated approval to Filspari ™ (sparsentan) to reduce proteinuria in adults ...
Data from SPARTACUS and PROTECT OLE to show significant proteinuria reduction when replacing RASi with FILSPARI and when FILSPARI is used in combination with SGLT2i New mechanistic data to show ...
(RTTNews) - Travere Therapeutics Inc. (TVTX) announced that new data further demonstrates the clinical benefit of FILSPARI (sparsentan) in IgA nephropathy (IgAN) and reinforces its potential in focal ...
If approved, FILSPARI would be the first and only FDA-approved treatment for FSGS, a rare kidney condition and a leading cause of kidney failure SAN DIEGO--(BUSINESS WIRE)--Travere Therapeutics, Inc. ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results